Novo Nordisk Expects Sales Drop in 2026 Amid Rising Competition

Novo Nordisk forecasts 5-13% sales decline for 2026 as Ozempic and Wegovy face intense competition from Eli Lilly and generics, plus US drug pricing pressures.